- Home
- ELVN vs ROOT Comparison
ELVN vs ROOT Comparison
Compare ELVN & ROOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELVN
- ROOT
- Stock Information
- Founded
- ELVN 2016
- ROOT 2015
- Country
- ELVN United States
- ROOT United States
- Employees
- ELVN N/A
- ROOT N/A
- Industry
- ELVN Biotechnology: Pharmaceutical Preparations
- ROOT Property-Casualty Insurers
- Sector
- ELVN Health Care
- ROOT Finance
- Exchange
- ELVN Nasdaq
- ROOT Nasdaq
- Market Cap
- ELVN 927.8M
- ROOT 2.3B
- IPO Year
- ELVN 2020
- ROOT 2020
- Fundamental
- Price
- ELVN $20.73
- ROOT $124.70
- Analyst Decision
- ELVN Strong Buy
- ROOT Buy
- Analyst Count
- ELVN 5
- ROOT 6
- Target Price
- ELVN $41.20
- ROOT $134.80
- AVG Volume (30 Days)
- ELVN 747.2K
- ROOT 448.2K
- Earning Date
- ELVN 08-12-2025
- ROOT 08-06-2025
- Dividend Yield
- ELVN N/A
- ROOT N/A
- EPS Growth
- ELVN N/A
- ROOT N/A
- EPS
- ELVN N/A
- ROOT 3.16
- Revenue
- ELVN N/A
- ROOT $1,271,000,000.00
- Revenue This Year
- ELVN N/A
- ROOT $22.06
- Revenue Next Year
- ELVN N/A
- ROOT $10.86
- P/E Ratio
- ELVN N/A
- ROOT $39.46
- Revenue Growth
- ELVN N/A
- ROOT 98.66
- 52 Week Low
- ELVN $13.30
- ROOT $34.04
- 52 Week High
- ELVN $30.03
- ROOT $181.14
- Technical
- Relative Strength Index (RSI)
- ELVN 52.08
- ROOT 40.50
- Support Level
- ELVN $19.22
- ROOT $122.24
- Resistance Level
- ELVN $21.90
- ROOT $130.33
- Average True Range (ATR)
- ELVN 1.49
- ROOT 7.74
- MACD
- ELVN -0.19
- ROOT -1.68
- Stochastic Oscillator
- ELVN 39.43
- ROOT 9.87
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
About ROOT Root Inc.
Root Inc develops and launches a direct-to-consumer personal automobile insurance and mobile technology company. It generates revenue from the sales of auto insurance policies within the United States.